

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.3	28.09.2024	19255-00024	Date of first issue: 07.10.2014

**SECTION 1: IDENTIFICATION**

Product name : Infliximab Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : Building A - Level 1/26 Talavera Rd  
Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Not a hazardous substance or mixture.

**GHS label elements**

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	>= 60 -<= 100
Infliximab	170277-31-3	>= 10 -< 30

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
2.3	28.09.2024	19255-00024	06.04.2024
			Date of first issue: 07.10.2014

---

		When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
Notes to physician	:	Treat symptomatically and supportively.

---

**SECTION 5. FIREFIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
---	---	--

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue:
2.3	28.09.2024	19255-00024	06.04.2024
			Date of first issue: 07.10.2014

---

- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**SECTION 7. HANDLING AND STORAGE**

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.
- Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## Infliximab Formulation

Version 2.3	Revision Date: 28.09.2024	SDS Number: 19255-00024	Date of last issue: 06.04.2024 Date of first issue: 07.10.2014
----------------	------------------------------	----------------------------	---

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m <sup>3</sup>	AU OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Infliximab	170277-31-3	TWA	150 µg/m <sup>3</sup>	Internal

**Engineering measures** : Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

## Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : For prolonged or repeated contact use protective gloves.  
Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:  
Safety goggles

Skin and body protection : Skin should be washed after contact.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Amorphous powder

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : 7.2

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

**Infliximab Formulation**

Version 2.3	Revision Date: 28.09.2024	SDS Number: 19255-00024	Date of last issue: 06.04.2024 Date of first issue: 07.10.2014
----------------	------------------------------	----------------------------	---

---

Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	1 g/cm <sup>3</sup>
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means.

## Infliximab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.3	28.09.2024	19255-00024	Date of first issue: 07.10.2014

---

Can react with strong oxidizing agents.

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

**Acute toxicity**

Not classified based on available information.

**Components:****Sucrose:**

Acute oral toxicity	:	LD50 (Rat): 29,700 mg/kg
---------------------	---	--------------------------

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Infliximab:**

Remarks	:	No data available
---------	---	-------------------

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Infliximab:**

Remarks	:	No data available
---------	---	-------------------

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.3	28.09.2024	19255-00024	Date of first issue: 07.10.2014

---

**Components:****Sucrose:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

**Infliximab:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: Chromosomal aberration  
Test system: human lymphoblastoid cells  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Method: OECD Test Guideline 474  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Infliximab:**

Effects on fertility : Test Type: Fertility  
Species: Mouse  
Application Route: Intravenous injection  
Fertility: NOAEL: 40 mg/kg body weight  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Mouse, female  
Application Route: Intravenous injection  
Duration of Single Treatment: 6 - 12 d  
General Toxicity Maternal: NOAEL: 40 mg/kg body weight  
Teratogenicity: NOAEL F1: 40 mg/kg body weight  
Developmental Toxicity: NOAEL F1: 40  
Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight  
Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.3	28.09.2024	19255-00024	Date of first issue: 07.10.2014

---

**STOT - repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Infliximab:**

Species	:	Mouse
NOAEL	:	40 mg/kg
Application Route	:	Intravenous
Exposure time	:	6 Months
Number of exposures	:	daily

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Infliximab:**

Inhalation	:	Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, Fatigue, Headache, Back pain
------------	---	---

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Infliximab:****Ecotoxicology Assessment**

Acute aquatic toxicity	:	No data available
------------------------	---	-------------------

Chronic aquatic toxicity	:	No data available
--------------------------	---	-------------------

**Persistence and degradability**

No data available

**Bioaccumulative potential****Components:****Sucrose:**

Partition coefficient: n-octanol/water	:	Pow: < 1
--	---	----------

**Mobility in soil**

No data available

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.3	28.09.2024	19255-00024	Date of first issue: 07.10.2014

**Other adverse effects**

No data available

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

**IATA-DGR**

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

**IMDG-Code**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****ADG**

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.3	28.09.2024	19255-00024	Date of first issue: 07.10.2014

---

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Hazchem Code	:	Not applicable

**Special precautions for user**

Not applicable

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Therapeutic Goods (Poisons Standard) Instrument : No poison schedule number allocated (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

---

**SECTION 16: ANY OTHER RELEVANT INFORMATION****Further information**

Revision Date : 28.09.2024  
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average  
AU OEL / TWA : Exposure standard - time weighted average

**Infliximab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.3	28.09.2024	19255-00024	Date of first issue: 07.10.2014

---

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN